S&P Futures
4,120.75+0.50(+0.01%)Dow Futures
33,638.00+7.00(+0.02%)Nasdaq Futures
13,817.25+8.50(+0.06%)
Naturally Splendid Enterprises Ltd. (50N.F)
Chart Events
Performance Outlook
| Previous Close | 0.0305 |
| Open | 0.0305 |
| Bid | 0.0000 x 2000000 |
| Ask | 0.0000 x 2000000 |
| Day's Range | 0.0305 - 0.0305 |
| 52 Week Range | 0.0100 - 0.0894 |
| Volume | 2,000 |
| Avg. Volume | 354 |
| Market Cap | 8.735M |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0290 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- ACCESSWIRE
Naturally Splendid Appoints Marketing Executive to Advisory Board
VANCOUVER, BC / ACCESSWIRE / April 6, 2021 / Naturally Splendid Enterprises Ltd. ("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N)(TSXV:NSP)(OTC PINK:NSPDF) is pleased to announce the addition of Marketing Executive, Drago Adam to their Advisory Board.
- ACCESSWIRE
Naturally Splendid Announces Update on Health Canada Approved COVID-19 Clinical Trial and Strategic Outlook for Development of Cavaltinib(TM)
VANCOUVER, BC / ACCESSWIRE / April 1, 2021 / Naturally Splendid Enterprises Ltd.("Naturally Splendid", "NSE" or "the Company") (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) provides an update on the Health Canada approved, COVID-19 phase 2 clinical trial and strategic outlook for Plasm Pharmaceutical and development of the target drug CavaltinibTM.
- ACCESSWIRE
Naturally Splendid Prepares Another Container of Hemp for South Korea
VANCOUVER, BC / ACCESSWIRE / March 30, 2021 / Naturally Splendid Enterprises Ltd. ("Naturally Splendid") (TSX-V:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce the Company has received a Purchase Order for another container of hulled hemp seed from its roster of clients in South Korea.
